Discovery Laboratories to Host a Conference Call to Provide an Overview of Its Program for Surfaxin(R) U.S. Marketing Authorization
WARRINGTON, Pa., Jan. 27, 2011 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) will host a conference call on Tuesday, February 1, 2011, at 10:00 AM EST. Management will provide an overview of Discovery Labs' efforts to gain U.S. Food and Drug Administration (FDA) marketing approval of Surfaxin® for the prevention of respiratory distress syndrome (RDS) in premature infants.